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ABSTRACT 110 
Time to fall asleep (sleep latency) is a major determinant of sleep quality. Chronic, long 111 
sleep latency is a major characteristic of sleep-onset insomnia and/or delayed sleep 112 
phase syndrome. In this study we aimed to discover common polymorphisms that 113 
contribute to the genetics of sleep latency. We performed a meta-analysis of genome-114 
wide association studies (GWAS) including 2 572 737 single nucleotide polymorphisms 115 
(SNPs) established in seven European cohorts including 4 242 individuals.  116 
We found a cluster of three highly correlated variants (rs9900428, rs9907432 and 117 
rs7211029) in the RNA binding protein fox-1 homolog 3 gene (RBFOX3) associated 118 
with sleep latency (p-values = 5.77 *10-08, 6.59*10-08 and 9.17*10-08). These SNPs were 119 
replicated in up to 12 independent populations including 30 377 individuals (p-values = 120 
1.5*10-02, 7.0*10-03 and 2.5*10-03; combined meta-analysis p-values = 5.5*10-07, 5.4*10-121 
07 and 1.0*10-07). A functional prediction of RBFOX3 based on co-expression with other 122 
genes shows that this gene is predominantly expressed in brain (p-value = 1.4*10-316) 123 
and the central nervous system (p-value = 7.5*10-321). The predicted function of 124 
RBFOX3 based on co-expression analysis with other genes shows that this gene is 125 
significantly involved in the release cycle of neurotransmitters including GABA and 126 
various monoamines (p-values < 2.9*10-11) that are crucial in triggering the onset of 127 
sleep. To conclude, in this first large-scale GWAS of sleep latency we report a novel 128 
association of variants in RBFOX3 gene. Further, a functional prediction of RBFOX3 129 
supports the involvement of RBFOX3 with sleep latency. 130 
 131 




Sleep occurs during defined periods within the 24 hour cycle 1. Its timing and duration 135 
is considered to be regulated by two processes; (I) a circadian process (i.e., being awake 136 
during the day and asleep during night) and (II) a homeostatic process that represents 137 
the sleep pressure accumulating during wakefulness, i.e. the longer one is awake, the 138 
greater sleep pressure and the greater will be the duration of sleep when permitted 2. 139 
Sleep latency, i.e., the duration it takes to fall asleep, is a measure of sleep quality 140 
computed as the time interval between “lights out” until the onset of sleep. Photic 141 
information from the retina is projected to the suprachiasmatic nucleus (SCN) via the 142 
retino-hypothalamic tract. In humans, the SCN is considered the pacemaker for the 143 
timing of daily sleep-wake behavior and consists of approximately 10 000 neurons 144 
located on both sides of the midline above the optic chiasma, about 3 cm behind the 145 
eyes 3,4. At night, the SCN signals the release of melatonin – a hormone produced by the 146 
pineal gland that promotes sleep. Sleep latency may be assessed using self-reports, 147 
actigraphy, or with polysomnography. Normal sleepers are known to provide estimates 148 
of sleep latency that correlate well with polysomnographic measures 5,6. Previous 149 
studies show that sleep latency is largely independent of an individual’s chronotype 7.  150 
Inter-individual differences in sleep latency are caused by both genetic and non-151 
genetic factors. The latter include gender 8,9, age 8, consumption of stimulants 10, dietary 152 
intake 11, sedentary life 12 and illnesses, such as depression 13. Persistent increased sleep 153 
latency is a major characteristic of delayed sleep phase syndrome 14 and/or sleep-onset 154 
insomnia 15-18. Prolonged sleep latency may shorten sleep duration and may lead to a 155 
wide range of problems including irritability, cognitive impairment, depression and loss 156 
of productivity as well as accident rates due to sleepiness. Increased sleep latency has 157 
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also been associated with poor academic performance in children and adolescents 19. 158 
While very long sleep latency can lead to sleep deprivation, very short sleep latency can 159 
reflect sleep deprivation (i.e., ‘sleep debt’ due to insufficient sleep normally shortens 160 
sleep latency). Unusually short sleep latency also may indicate disorders of excessive 161 
sleepiness (e.g., narcolepsy). When giving individuals the opportunity to sleep during 162 
the day, sleep latency is used as an objective measure of daytime sleepiness in the 163 
diagnosis of sleep disorders.  164 
Heritability of sleep latency is estimated to be around 17-44% 20-22. Although 165 
much is known about the environmental factors that can prolong sleep latency, we know 166 
little about the genetic influences on sleep latency. In this study, we performed a meta-167 
analysis of unpublished genome-wide association studies (GWAS) on sleep latency in 168 
order to elucidate genetic associations with this trait. 169 
 170 
MATERIALS AND METHODS: 171 
Study populations (Stage 1/ Discovery cohorts) 172 
We meta-analyzed data from seven GWAS comprising of 4 242 subjects with European 173 
ancestry (Tables S1 & S2). The participating cohorts in the gene discovery phase 174 
included the Erasmus Rucphen Family (ERF), Estonian Genome Center 175 
(EGP/EGCUT), CROATIA-Korcula, the Micro-isolates in South Tyrol Study 176 
(MICROS), Cooperative health research in the Region of Augsburg (KORA), the 177 
Netherlands Study of Depression and Anxiety (NESDA) and the Orkney Complex 178 
Disease Study (ORCADES) (Tables S1 & S2). A detailed description of the included 179 
studies is provided in the supplemental text. All studies in the discovery cohort used the 180 
Munich Chronotype Questionnaire (MCTQ)23 to assess sleep latency. Subjects were 181 
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asked to report how long they take to fall asleep on free and workdays. Free days sleep 182 
latency was used in the analyses of those cohorts, where a person’s sleep pattern is not 183 
influenced by professional duties 24 (Figure S1). The question from the MCTQ used to 184 
assess sleep latency (in minutes): “I need … minutes to fall asleep”. Sleep duration was 185 
calculated by subtracting sleep onset from sleep end. Mid-sleep was calculated as the 186 
midpoint between sleep onset and waking on free days 25. The quality control was 187 
centralized and the inclusion criteria were: (i) no use of an alarm clock on free days; (ii) 188 
no shift-work during the last three months; and (iii) no use of sleep medication 189 
(benzodiazepines and other pharmacological agents that influence sleep; see Table S3). 190 
Informed consent was obtained from all study participants and an appropriate local 191 
committee approved the study protocols. 192 
 193 
Study populations (Stage 2/ Replication cohorts) 194 
The replication stage included 12 independent cohorts (see supplementary text; Figure 195 
S1). The descriptive statistics are provided in Table S1. Inclusion criteria were: 1) sleep 196 
assessment with any available tool, and 2) No use of sleep medication (Figure S1). Five 197 
replication cohorts (MrOS, RS-I, RS-II, RS-III and SOF) used the Pittsburg Sleep 198 
Quality Index (PSQI) to assess sleep (Table S2), which uses only a single measure for 199 
sleep assessment and does not distinguish between sleep on free and working days. 200 
 201 
Genotyping & Imputation: 202 
Both discovery and replication cohorts were genotyped on a variety of platforms 203 
(Affymetrix 250K, Illumina 318K, Illumina 370K, Illumina 610k; Perlegen 600K; 204 
Affymetrix 1000K). Quality control was done in each group separately. The overall 205 
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criteria were to exclude individuals with low call rate, excess heterozygosity, and 206 
gender mismatch, and exclude variants that were out of Hardy-Weinberg equilibrium, 207 
had low minor allele frequency (MAF) or low call rate (Table S2). In EGCUT1 study 208 
where the genome-wide data was not available, the 2 most significant SNPs for which a 209 
TaqMan assay was available were genotyped (Table S4). Imputations of non-genotyped 210 
SNPs in the discovery cohorts were carried out within each study using either MACH 211 
26,27 or IMPUTE 28,29, and HapMap CEU v21a or v22 as reference (Table S2). Genetic 212 
imputations in the replication cohorts were performed using MACH, IMPUTE, 213 
minimac or BimBam (Table S2). Of the three SNPS rs9907432 was genotyped in most 214 
replication cohorts while rs9900428 was imputed in all replication cohorts (Table S4). 215 
The data are available in the GWAS Central database, under the accession number 216 
HGVST1836 (http://www.gwascentral.org/study/HGVST1836). 217 
 218 
Methylation & Expression 219 
The Infinium Human Methylation 450 array (Illumina, San Diego, CA) was used to 220 
quantify genome-wide DNA methylation for 748 samples from the Rotterdam study 221 
(RS-III) covering 485 577 CpG sites in the genome. Bisulfite conversion followed by 222 
amplification, hybridization and imaging were performed according to standard 223 
protocols. Illumina GenomeStudio software was used to estimate β score from intensity. 224 
Quality-control (QC) steps included removal of signal probes with a detection of P-225 
value > 0.01; and exclusion of probes with low intensity. Samples with a call rate < 226 
99% were removed from the dataset. SWAN package for R software was used to 227 
normalize remaining CpG sites and correct for batch effects.  228 
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        RNA from the same samples was obtained (PAXgene) and hybridized to Illumina 229 
HumanHT-12 arrays. Raw probe intensity was obtained using BeadStudio. Gene 230 
expression data was quantile-normalized to the median distribution, and subsequently 231 
log2 transformed. The probe and sample means were centered to zero. Probes that had a 232 
detection p-value < 0.05 in > 10% of the samples were removed from the analysis. The 233 
final analysis included 21 328 probes, which were significantly expressed in blood. 234 
 235 
 Statistical analysis 236 
Heritability Analysis 237 
Heritability analysis of sleep latency was performed in the family based ERF cohort 238 
using Sequential Oligogenic Linkage Analysis Routines (SOLAR) 30. SOLAR uses 239 
likelihood ratio tests to evaluate heritability by comparing a purely polygenic model 240 
with a sporadic model in the case of testing heritability. The ERF cohort forms one 241 
large family, which consists of more than 23 000 members spanning over 23 242 
generations. Since this uniquely large family is too large to be analyzed with SOLAR, 243 
we cut it into smaller pedigrees (3 to 5 generations) using the Pedcut software 31 for the 244 
heritability analysis. A natural log transformation was applied to the trait before 245 
estimating the heritability. The heritability was estimated with the ‘polygenic screen’ 246 
option and using age and sex as covariates in the model. The estimate was then 247 
compared to the heritability estimate derived from the polygenic analysis of GenABEL 248 





Genome-wide Association Analysis 253 
Individual GWAS was performed using linear regression (under additive 254 
model), natural log of sleep latency as the dependent variable, SNP allele dosage as 255 
predictor and age and sex as covariates. CROATIA-Korcula and ORCADES 256 
additionally used first three principal components as covariates in the association 257 
model. The association analyses were conducted in ProbABEL 32-34 or SNPTEST 35. For 258 
cohorts with related individuals (ERF, MICROS, CROATIA-Korcula, ORCADES), a 259 
linear mixed model in ProbABEL using the “mmscore” option was used to account for 260 
familial relationships. The mmscore option performs the score test that uses the inverse 261 
variance-covariance object estimated from the genetic data and returned from the 262 
“polygenic” function of GenABEL 32 to correct for familial relationships. This is a 263 
slightly modified FASTA method developed by Abecasis et al. 36.  264 
Since all three SNPs show no heterogeneity across the cohorts (p-values > 0.7) 265 
(Table 1), a fixed effects meta-analysis was conducted using the inverse variance 266 
weighted method as implemented in METAL 267 
(http://www.sph.umich.edu/csg/abecasis/metal/). All SNPs that had a MAF < 0.01 and 268 
low imputation quality (Rsq/proper_info < 0.3) were dropped from the meta-analysis. 269 
Genomic control correction was also applied to all cohorts prior to the meta-analysis.  270 
For the SNPs that approached genome-wide significance (p-value < 5x10-08) we 271 
performed replication in up to 12 independent cohorts using the same model as in the 272 
initial GWAS. In the replication cohorts, among the family based studies, ERF_ext used 273 
SOLAR, FHS used LMEKIN package of R software (http://www.r-project.org/), 274 
CROATIA-Split used the “mmscore” option in ProbABEL while QIMR used MERLIN 275 
to account for family structure. Other population based cohorts used SPSS, PLINK 276 
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(http://pngu.mgh.harvard.edu/purcell/plink/) 37 or R software to perform association 277 
analysis (Table S2). Meta-analysis was performed using square-root of the sample size 278 
as weights 38. 279 
 280 
Methylome-wide association analysis 281 
Top SNPs from the meta-analysis of GWAS were tested for association with genome-282 
wide methylation (CpG) sites by performing linear regression analyses of methylation 283 
sites on each of the three SNPs while adjusting for age, sex, technical covariates 284 
including batch effects and blood cell counts (granulocytes, lymphocytes, monocytes, 285 
erythrocytes and platelets) in R software. 286 
  287 
Gene functional prediction and network analysis 288 
Prediction of gene function can be conducted using a guilt-by-association 289 
approach: e.g., if there are 100 genes that are known to be involved in apoptosis, 290 
identification of a gene that is strongly co-expressed with these 100 genes suggests that 291 
this gene is likely to be involved in apoptosis as well. As such co-expression data can be 292 
used to predict likely functions for genes. However, important to realize is that some 293 
phenomena exert very strong transcriptomic effects and therefore will overshadow more 294 
subtle effects. In order to be able to identify such subtle relationships as well, we 295 
conducted a principal component analysis on an unprecedented scale 39: We collected 296 
gene expression data for three different species (homo sapiens, mus musculus and rattus 297 
norvegicus) from the Gene Expression Omnibus. We confined analyses to four different 298 
Affymetrix expression platforms (Affymetrix Human Genome U133A Array, 299 
Affymetrix Human Genome U133 Plus 2.0 Array, Affymetrix Mouse Genome 430 2.0 300 
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Array and Affymetrix Rat Genome 230 2.0 Array). For each of these platforms we 301 
downloaded the raw CEL files (20 108, 43 278, 18 639 and 6 124 arrays, respectively), 302 
and used RMA for normalization. We could run RMA on all samples at once for the 20 303 
108 Human Genome U133A Array, 18 639 Mouse Genome 430 2.0 Array and 6 123 304 
Rat Genome 230 2.0 Array. For the 43 278 Human Genome U133 Plus 2.0 Array 305 
samples we ran RMA in eight batches due to its size, by randomly assigning the 306 
samples to one of these batches. We subsequently conducted quality control (QC) on 307 
the data. We first removed duplicate samples, and then conducted a principal 308 
component analysis (PCA) on the sample correlation matrix. The first principal 309 
component (PCqc) on such a matrix describes nearly always a constant pattern 310 
(dominating the data), which explains around 80-90% of the total variance 40,41. This 311 
pattern can be regarded as probe-specific variance, independent of the biological sample 312 
hybridized to the array. The correlation of each individual microarray with this PCqc 313 
can be used to detect outliers, as arrays of lesser quality will have a lower correlation 314 
with the PCqc. We removed samples that had a correlation R < 0.75. After QC in total 315 
77 840 different samples remained for downstream analysis (54 736 human samples, 17 316 
081 mouse samples, 6 023 rat samples). Although this QCed dataset can be well used 317 
for the aforementioned guilt-by-association co-expression analysis, we reasoned that the 318 
presence of profound effects on many genes will make it difficult to identify the more 319 
subtle relationships that exist between genes. Therefore, we conducted a PCA on the 320 
probe correlation matrix, resulting in the identification of in total 2 206 robustly 321 
estimated principal components (377 for Human Genome U133A, 777 for Human 322 
Genome U133 Plus 2.0, 677 for Mouse Genome 430 2.0 and 375 for Rat Genome 230 323 
2.0) by requiring a Cronbach's alpha > 0.70 for each individual principal component. 324 
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Jointly these components explain between 79% and 90% of the variance in the data per 325 
Affymetrix expression platform, and many of these are well conserved across the three 326 
species. 327 
Subsequent Gene Set Enrichment Analysis (GSEA) revealed that each of these 2 328 
206 components are significantly enriched (False discovery rate < 0.05) for at least one 329 
GO term, KEGG, BioCarta or Reactome pathway, indicating that these components are 330 
describing biologically relevant but often diverse phenomena. While per species the 331 
very first components describe profound effects on expression (i.e. many enriched 332 
pathways and GO terms), the other components are potentially equally biologically 333 
relevant, as each of the components describe certain biological phenomena. We 334 
therefore used the individual components and integrated the different platforms and 335 
species by collapsing the probe identifiers to human Ensembl genes and used orthology 336 
information from Ensembl for the mouse and rat platform, resulting in a harmonized 337 
matrix of 19 997 unique Ensembl genes x 2 206 principal components. 338 
We subsequently predicted the most likely Gene Ontology (GO) biological 339 
process using the following strategy: (i) we first ascertained each individual GO term 340 
and assessed per PC whether the genes that were explicitly annotated with this GO term 341 
showed a significant difference from the genes that were not annotated with this GO 342 
term using a T-Test; (ii) we converted the resulting P-Value into an 'enrichment' Z-343 
Score (to ensure normality); and (iii) we subsequently investigated RBFOX3 and 344 
correlated the 2 206 PC eigenvector coefficients of RBFOX3 with each GO term by 345 
taking the 2 206 'enrichment' Z-Scores as the expression profile for that GO term. A 346 
significant positive correlation means RBFOX3 has an expression profile that is 347 
comparable to the GO term. We have visualized this method at 348 
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www.genenetwork.nl/genenetwork (click on “Method”). In order to correct for multiple 349 
testing, we permuted Ensembl gene identifiers: using permuted data we redid the 350 
‘enrichment’ Z-score calculation and investigated how strong RBFOX3 correlated with 351 
permuted pathway. We repeated this analysis 100 times, allowing us to determine which 352 
of these predictions were significant (controlling to the false discovery rate of 0.05). We 353 
used the same procedure to predict in which BioCarta and Reactome pathways RBFOX3 354 
is involved. 355 
 356 
RESULTS 357 
A basic description of the study populations is given in Table S1. The heritability of 358 
sleep latency using the pedigree data of the Erasmus Rucphen Family (ERF) study was 359 
estimated to be 0.18 (SE = 0.112, p-value = 0.05) (see methods section), which is 360 
consistent with earlier findings of heritability for this trait 21 and also comparable to the 361 
heritability estimate (h2 = 0.20) derived from the genome-wide genotype data (see 362 
methods section for details) of the same cohort. The quantile-quantile plot of the meta-363 
analysis shows no inflation of the chi-square statistic since the genomic control inflation 364 
factor (λ) is 1.01 (Figure S2). The meta-analysis of GWAS produced a cluster of three 365 
borderline genome-wide significant SNPs (Table 1; Figure 1, and Figure S3) on 366 
chromosome 17q25. The highest-ranking SNP rs9900428 hg18.chr17:g.74651323G>A) 367 
(p-value = 5.7*10-08) had a minor-allele frequency (MAF) of 0.20-0.33, with the 368 
imputation quality ranging from 0.85 to 0.99 across all cohorts. The effect size (β = -369 
0.094) and the direction of the risk were consistent across all cohorts (Table 1). The 370 
other two SNPs rs9907432 (hg18.chr17:g.74651967:G>A) (p-value = 6.5*10-08) and 371 
rs7211029 (hg18.chr17:g.74652903C>T) (p-value = 9.1*10-08) were in linkage 372 
 15
disequilibrium (LD; r2 = 0.95) with rs9900428 (Figure 1, Figure S4). Figure 2 shows the 373 
mean sleep latency per genotype category for all the discovery cohorts for the three 374 
SNPs unadjusted for age and gender. Compared to the homozygote carriers of the 375 
reference allele (pooled average sleep latency = 16.4 min), the homozygote carriers 376 
(pooled average sleep latency = 13.5 minutes) of the minor allele are estimated to have 377 
a sleep latency of on average approximately three minutes less (a reduction of 18%) and 378 
the heterozygote carriers (pooled average sleep latency = 15.5 minutes) about 1 minute 379 
less (a reduction of about 6%) (Figure 2).  380 
 We attempted to replicate these three SNPs in up to 12 independent cohorts 381 
(Tables S2 & S4). SNP rs9900428 was available in-silico in 11 cohorts, while 382 
rs9907432 and rs7211029 were available in all 12 cohorts. The replication analyses 383 
showed consistency in the direction of the effect across most replication cohorts (Figure 384 
3). The meta-analysis of the replication cohorts yielded significant evidence of 385 
association of rs9900428 (p-value = 1.5*10-02), rs9907432 (p-value = 7.1*10-03) and 386 
rs7211029 (p-value = 2.5*10-03) with sleep latency (Table 2). The three SNPs are 387 
intronic to the RNA binding protein fox-1 homolog 3 (RBFOX3 also known as 388 
HRNBP3; Figure 1) and lie in the region with active regulatory elements (ENCODE) 389 
containing the H3K27ac mark and methylation marks. H3K27ac is an important 390 
enhancer mark that can distinguish between active and poised enhancer elements. Such 391 
enhancer elements are known to affect the expression of proximal genes and cluster 392 
near the genes they regulate 42. We investigated the 3 SNPs further using the methylome 393 
data of RS. The 3 SNPs were methylome-wide significantly associated (p-value = 394 
8.1*10-9, FDR = 0.004) with the CpG site: cg16185152 in the RBFOX3 gene. We 395 
attempted to investigate the effect of methylation on gene expression, there was, 396 
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however, only one probe for the RBFOX3 gene in the HumanHT-12_V4_Illumina 397 
450K RNA expression array, which was removed in the quality control.  398 
A gene-network analysis of RBFOX3 using gene network tool 399 
(http://genenetwork.nl:8080/GeneNetwork/) shows strongest co-expression with the 400 
hippocalcin gene HPCA followed by SNCB, CABP1, JPH3, CPLX2, GABRA6, GABRD, 401 
NRXN3, RBFOX1, RTN4R, CNTN2 and WSCD2 among others (Figure S5). A functional 402 
prediction of the gene showed involvement in the biological processes of synaptic 403 
functioning, membrane depolarization, gamma-aminobutyric acid (GABA) signaling 404 
and nervous system development (Tables S5 & S6) and in dopamine, serotonin and 405 
glutamate neurotransmitters release cycle (Table S7). RBFOX3 is expressed most 406 
strongly in various parts of the brain (brain, p-value = 1.4*10-316; central nervous 407 
system, p-value = 7.6*10-321; cerebral cortex, p-value = 1.0*10-174) including the 408 
hypothalamus (p-value = 9.7*10-10, AUC = 0.96) (Table S8), the locale of the SCN and 409 
a central part of the circadian clock.  410 
None of the three SNPs showed strong association with sleep duration or mid-411 
sleep, which is an indicator of the chronotype of an individual, Table S9. 412 
 413 
DISCUSSION 414 
In this first large-scale genome-wide association study of sleep latency, we report the 415 
association of novel variants located in the gene RBFOX3 with sleep latency. Our gene 416 
discovery phase consisted of a sample of 4 242 individuals from seven European 417 
populations, where sleep latency was assessed according to a common protocol. With 418 
this sample we discovered a cluster of three borderline genome-wide significant SNPs 419 
that were intronic to the gene RBFOX3. The replication of the three SNPs in up to 30 420 
 17
377 individuals from 12 independent cohorts showed significant association of the three 421 
variants and consistency in the direction of the effect estimates across most cohorts. A 422 
functional prediction of RBFOX3 based on a gene network analysis suggests significant 423 
involvement in the release cycle of neurotransmitters including GABA and various 424 
monoamines that are core to the human circadian clock, thus supporting the 425 
involvement of RBFOX3 with sleep latency.  426 
The RBFOX3 gene (also called Fox-3,Hrnbp3, Neun) is located on the long arm 427 
of chromosome 17 (17q25). It belongs to the Fox-1 family of genes and shows high 428 
homology to RBFOX1 (also called Fox-1, A2bp1, Hrnbp1) and RBFOX2 (also called 429 
Fox-2, Rbm9, Hrnbp2). RBFOX3 is a relatively new member of this family and was 430 
recently identified to code for neuronal nuclei (NeuN) protein 43. The Fox proteins are a 431 
highly conserved family of tissue specific splicing regulators 44. While RBFOX1 is 432 
expressed in neurons, muscles and heart, and RBFOX2 in ovary, whole embryo, neurons 433 
and muscles 45,46, the expression of RBFOX3 was detected exclusively in the post-434 
mitotic regions of embryonic mouse brain 44,47. RBFOX3 is believed to play a role in 435 
neuron-specific alternative splicing 43. Alternative splicing occurs most frequently in the 436 
brain 48,49, presumably to generate large numbers of neuronal cell types and to support 437 
their diverse functions 43. A recent analysis of rodent SCN (the biological clock) 438 
anatomy using antibody against NeuN protein shows that RBFOX3 has a unique 439 
distribution which is limited to a particular sector of the SCN 50. Mutations in the FOX-440 
1 genes lead to severe neuro-developmental phenotypes exhibiting mental retardation, 441 
epilepsy, and autism spectrum disorder 51-54. Further a very recent study on patients with 442 
developmental delay detected a translocation disrupting the intron 2 of the RBFOX3 443 
gene 55. Interestingly this patient additionally had sleeping difficulties. 444 
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Gene-network analysis of RBFOX3 showed strong co-expression with genes 445 
involved in calcium channel activity and GABA signaling. GABA-ergic sleep neurons 446 
of the ventro-lateral pre-optic nucleus are activated by the circadian clock and 447 
adenosine, which progressively accumulates in the brain during waking. In turn these 448 
sleep-active neurons begin to inhibit the wake-active neurons via the neurotransmitter 449 
GABA 56. GABA-A receptors are the site of action of a number of important 450 
pharmacologic agents including barbiturates, benzodiazepines (sleep inducing drugs), 451 
and ethanol 57,58. Polymorphisms in GABA-A receptors have been associated with 452 
insomnia 59. Functional prediction based on gene-network analysis shows significant 453 
involvement of RBFOX3 in the release cycle of various neurotransmitters including 454 
dopamine, serotonin and glutamate, GABA-A receptor activation and Ras-activation 455 
upon Ca2+ influx through the NMDA receptor. Photic information is communicated to 456 
the molecular clockworks by release of glutamate from retino-hypothalamic nerve 457 
terminals and stimulation of glutamate receptors on SCN neurons 60. Glutamate 458 
stimulation is followed by intra-cellular increases of cyclic adenosine monophosphate 459 
and Ca2+ and activation of a Ras-dependent signal cascade in the circadian clockwork. 460 
Non-photic signaling to the core subdivision of the SCN is conveyed through two major 461 
pathways including GABA-containing neurons derived from the thalamus and serotonin 462 
or 5-hydroxytryptamine (5-HT)–containing neurons derived from the midbrain. 463 
Serotonergic input to the SCN shifts the timing of the clock 60.  464 
Our study shows strong evidence of association of sleep latency with RBFOX3. 465 
The fact that the association signal was stronger in the discovery sample compared to 466 
the replication sample, even though the replication sample was six-fold larger, may be 467 
explained by the differences in phenotyping as well as by different cohort characteristics 468 
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(e.g., age). Notably, all discovery cohorts were European, whereas the replication 469 
cohorts were drawn additionally from North America and Asia; it is possible that socio-470 
cultural factors may have influenced sleep latency or how sleep latency was reported 471 
across cohorts. For instance, the phenotyping and quality control for the discovery 472 
cohorts was synchronized and centralized; all cohorts were assessed with Munich 473 
Chronotype Questionnaire (MCTQ), which, unlike other such instruments, assesses 474 
information separately for free days and working days. Our GWAS was based on sleep 475 
latency on free days, as sleep latency on workdays is heavily influenced by daily 476 
professional activities. Unfortunately, this distinction was not available for most of the 477 
replication cohorts. Moreover, exclusions in the GWAS discovery cohorts were based 478 
not only on sleep medication use but also on other drugs that are known to influence 479 
sleep. Sleep medication or for that matter any medication that has a sleep inducing 480 
effect reduces sleep latency 24, thereby introducing a potential bias on genetic studies of 481 
sleep latency. We also removed shift-workers and those using alarm clocks from the 482 
analysis in the discovery phase, which was not done in most replication cohorts. All of 483 
these factors likely affected the results in the replication phase. Nevertheless, despite a 484 
small effect size, the direction of association signal was consistent in most replication 485 
cohorts indicating the robustness of our finding. Furthermore, gene functional 486 
prediction and network analysis support the association of RBFOX3 variants with sleep 487 
latency. The predicted functioning of RBFOX3, including neurotransmitters’ release 488 
cycle and GABA-receptor activation strongly implicates a chronobiological 489 
explanation. However, further tests of association with various sleep disorders and 490 
functional analyses will provide a better insight into the relationship between RBFOX3 491 
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Titles and legends to figures 692 
Figure 1 693 
Regional association plot of sleep latency for the region 17q25. The plot was 694 
constructed using Locus Zoom (http://csg.sph.umich.edu/locuszoom/). The most 695 
significant SNP is depicted as a diamond and other SNPs in the region are depicted by 696 
circles. Various colors represent the extent of linkage disequilibrium with most 697 
significant SNP. The X-axis gives the position in mega bases and the Y-axis shows the 698 
negative logarithm of the p-values from the meta-analysis. 699 
Figure 2 700 
Means per genotype category for all the discovery cohorts for the three most 701 
significant SNPs. Black bars represent the mean sleep latency for the homozygous 702 
carriers of the effect allele. Y-axis depicts the sleep latency time in minutes. Panels A, B 703 
and C represent the effects of the SNPs in individual cohorts. Panel D represents the 704 
pooled average sleep latency per genotype category across all cohorts for the three 705 
SNPs (X-axis). Data used to generate this figure was not adjusted for age and sex. 706 
Figure 3 707 
Forest plot for the three SNPs at chromosome 17q25. On the left, the populations 708 
including the populations in the GWAS and the replication phase. The boxes represent 709 
the precision and horizontal lines representing the confidence intervals. Pooled estimate 710 
is the effect estimate from the meta-analysis of all cohorts. The horizontal axis 711 
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2. Study Populations (Stage 2/Replication cohorts) 718 
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4. Ethical statement 720 
Table S1 721 
Descriptive Statistics of stage1 (discovery) and stage2 (replication) cohorts. 722 
Table S2 723 
Genotyping and quality control in the stage 1 (discovery) and stage 2 (replication) 724 
cohorts.  725 
Table S3 726 
Pharmacological sleep agents. Drug groups and correspondent ATC codes used as 727 
exclusion criteria when selecting phenotyped subjects for the independent GWA 728 
studies. 729 
Table S4 730 
Summary of replicated SNPs in the replication cohorts. 731 
Table S5 732 
Results of Biological process prediction of RBFOX3 based on Gene Ontology. 733 
Table S6 734 
Results of pathway analysis of RBFOX3 based on BioCarta. 735 
Table S7 736 
Results of functional prediction of RBFOX3 based on Reactome. 737 
Table S8 738 
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Expression of RBFOX3 in various tissues. 739 
Table S9 740 
Association results of the SNPs with sleep duration and mid-sleep/chronotype. 741 
Figure S1 742 
Inclusion criteria for studies in discovery and replication phase. 743 
Figure S2 744 
Quantile-Quantile Plot for the meta-analysis. Horizontal axis shows the expected chi-745 
square distribution while the vertical axis shows the observed chi-square. Red line 746 
shows the distribution under the null hypothesis and the black dots represent a single 747 
point in the observed chi-square distribution. 748 
Figure S3 749 
Genome-wide association plot of sleep latency. The horizontal axis shows the whole 750 
autosomal genome divided into 22 chromosomes. The vertical axis shows the negative 751 
principal log of the p-values. Each dot represents a single nucleotide polymorphism. 752 
Figure S4 753 
Linkage disequilibrium (LD) plot for 17q25. The intensity of LD is depicted by the 754 
intensity of the color, i.e. the higher the intensity, the greater is the LD. 755 
Figure S5 756 
Gene network of RBFOX3 based on co-expression. The grey lines indicate positive 757 
co-expression and the blue lines indicate negative co-expression. The intensity of the 758 
color indicates the strength of the co-expression.759 
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SNP position(B36) allele gene maf chrom cohort EGP ERF KORA KORCULA MICROS NESDA ORKNEY Meta-analysis
N 933 740 548 610 693 540 206 4270 
rs9900428 74651323 G>A RBFOX3 0.20-0.33 17 β -0.106 -0.085 -0.158 -0.133 -0.082 -0.03 -0.122 -0.094
SE 0.051 0.024 0.057 0.067 0.055 0.064 0.104 0.017 
p-value 0.037 0.00036 0.0057 0.045 0.137 0.632 0.239 5.77*10-08 
Rsq 0.97 0.90 0.90 0.97 0.96 0.85 0.99  
PHET        0.823 
rs9907432 74651967 G>A RBFOX3 0.20-0.34 17 β -0.106 -0.083 -0.153 -0.127 -0.084 -0.0248 -0.1216 -0.092 
SE 0.0501 0.0234 0.0551 0.066 0.0543 0.0616 0.1031 0.017 
p-value 0.0354 0.00038 0.00568 0.053 0.1206 0.6874 0.2382 6.59*10-08 
Rsq 1.0 0.94 0.95 1.0 0.99 0.90 1.0  
PHET        0.814 
rs7211029 74652903 C>T RBFOX3 0.21-0.34 17 β -0.107 -0.083 -0.1499 -0.127 -0.083 -0.0119 -0.1215 -0.091 
SE 0.050 0.0234 0.0538 0.066 0.0544 0.0596 0.1034 0.017 
p-value 0.035 0.00038 0.0054 0.054 0.1249 0.8416 0.2397 9.17*10-08
Rsq 0.97 0.93 1.0 0.98 0.98 0.96 0.99
PHET  0.739
 
β Effect of the genetic variant 
SE Standard error of the effect estimate 
PHET p-value for heterogeneity 
Rsq imputation quality
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Table 2: Results of the replication of the top SNPs 
 
 cohort ARIC CHS EGCUT1 EGCUT2 ERF_ext FHS MROS NTR QIMR RS SOF SPLIT 
Meta-analysis 
Replication 
SNP N 3583 1533 5925 3540 143 2192 1849 1795 2280 5641 1480 416 30377 
rs9900428 
β 0.006 -0.011 NA -0.02 -0.128 -0.109 -0.012 -0.014 -0.034 -0.015 0.006 -0.095 -0.026 
SE 0.021 0.044 NA 0.027 0.139 0.068 0.026 0.014 0.031 0.019 0.035 0.079 0.010 
p-value 0.775 0.802 NA 0.461 0.357 0.109 0.644 0.317 0.273 0.408 0.864 0.231 0.015 
PHET             0.919 
rs9907432 
β 0.007 -0.009 -0.027 -0.022 -0.09 -0.109 -0.012 -0.012 -0.034 -0.016 0.005 -0.102 -0.026 
SE 0.021 0.044 0.019 0.027 0.133 0.069 0.026 0.014 0.031 0.0186 0.035 0.078 0.0097 
p-value 0.739 0.831 0.14 0.408 0.499 0.114 0.644 0.391 0.273 0.384 0.886 0.187 0.007 
PHET             0.949 
rs7211029 
β 0.007 -0.009 -0.028 -0.023 -0.223 -0.109 -0.012 -.024 -0.034 -0.016 0.005 -0.103 -0.030 
SE 0.021 0.044 0.019 0.027 0.139 0.069 0.026 0.016 0.031 0.019 0.035 0.078 0.0098 
p-value 0.739 0.831 0.142 0.398 0.109 0.116 0.644 0.133 0.272 0.384 0.886 0.186 0.0025 
PHET             0.792 
 
β Effect of the genetic variant 
SE Standard error of the effect estimate 
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